Biogen (BIIB) Operating Margin (2009 - 2026)
Biogen (BIIB) posted quarterly Operating Margin of 11.43% for Q1 2026, up 165.0% year-over-year from 4.31% in Q1 2025, and up 52.74% on a QoQ basis from 24.19% in Q4 2025.
Biogen (BIIB) Operating Margin (2009 - 2026) Analysis & Trends
Biogen (BIIB) has reported Operating Margin for 18 consecutive years, with 11.43% the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Margin rose 165.0% year-over-year to 11.43%; the TTM figure through Mar 2026 stood at 8.18% (down 161.0% YoY), while the FY2025 annual figure was 8.57%, down 439.0% from the prior year.
- Operating Margin came in at 11.43% for Q1 2026 at Biogen, up from 24.19% in the prior quarter.
- The five-year high for Operating Margin was 35.94% in Q3 2022, with the low at 31.65% in Q3 2023.
- Average Operating Margin over 5 years is 0.72%, with a median of 3.38% recorded in 2024.
- Across the five-year window, Operating Margin sank 6759 bps in 2023 and surged 2404 bps in 2024, its largest moves.
- Year by year, Operating Margin stood at 17.29% in 2022, then tumbled by 69 bps to 5.35% in 2023, then plunged by 322 bps to 11.9% in 2024, then tumbled by 103 bps to 24.19% in 2025, then soared by 53 bps to 11.43% in 2026.
- According to Business Quant data, Operating Margin over the past three periods registered 11.43%, 24.19%, and 4.62% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 47.98% |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 26.44% |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 26.60% |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 29.51% |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -47.46% |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 30.94% |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 37.16% |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | -286.83% |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | -11.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -11.43% |
| Dec 31, 2025 | -24.19% |
| Sep 30, 2025 | -4.62% |
| Jun 30, 2025 | 5.25% |
| Mar 31, 2025 | -13.09% |
| Dec 31, 2024 | -11.90% |
| Sep 30, 2024 | -7.61% |
| Jun 30, 2024 | 6.19% |
| Mar 31, 2024 | -3.38% |
| Dec 31, 2023 | 5.35% |
| Sep 30, 2023 | -31.65% |
| Jun 30, 2023 | 4.70% |
| Mar 31, 2023 | -9.11% |
| Dec 31, 2022 | 17.29% |
| Sep 30, 2022 | 35.94% |
| Jun 30, 2022 | 30.34% |
| Mar 31, 2022 | 24.12% |
| Dec 31, 2021 | 21.48% |
| Sep 30, 2021 | 28.57% |
| Jun 30, 2021 | 17.50% |